Accès ouvert
2024
article
OpenAlex
Laura S. Samples, Jenna M. Voutsinas, Bita Fakhri, Sirin Khajavian et autres
ABSTRACT: Although Bruton tyrosine kinase inhibitors (BTKis) are generally well tolerated and less toxic than chemotherapy alternatives used to treat lymphoid malignancies, BTKis like ibrutinib have the potential to cause new or worsening hypertension (HTN). Little is known about the optimal treatment …
us, jp
(code pays fourni par la source)
2019
article
OpenAlex
Anthony R. Mato, Jakub Svoboda, Eline T. Luning Prak, Stephen J. Schuster et autres
Introduction: Preclinical data suggest that PD-1 mediates immune evasion in CLL, however clinical data indicate that pembrolizumab (pembro) monotherapy is ineffective in r/r CLL patients (pts) (0% ORR; Ding, BLOOD 2017). We hypothesized synergistic activity with PD-1 + PI3K blockade. Umbralisib (Umbra), …
us, Afrique du Sud
(code pays fourni par la source)
2018
conference-abstract
OpenAlex
Anthony R. Mato, Jakub Svoboda, Eline T. Luning Prak, Stephen J. Schuster et autres
Abstract Introduction: Preclinical data suggest that PD-1 and PD-L1/PD-L2 mediate immune evasion in CLL. However, clinical data (Ding, BLOOD 2017) demonstrate that pembrolizumab monotherapy (pembro) is ineffective in relapsed/refractory (r/r) CLL patients (pts) (ORR 0%, med PFS 2.4 months). Additional data with …
us
(code pays fourni par la source)